Literature DB >> 14718938

Population genetic screening programmes: principles, techniques, practices, and policies.

Béatrice Godard1, Leo ten Kate, Gerry Evers-Kiebooms, Ségolène Aymé.   

Abstract

This paper examines the professional and scientific views on the principles, techniques, practices, and policies that impact on the population genetic screening programmes in Europe. This paper focuses on the issues surrounding potential screening programmes, which require further discussion before their introduction. It aims to increase, among the health-care professions and health policy-makers, awareness of the potential screening programmes as an issue of increasing concern to public health. The methods comprised primarily the review of the existing professional guidelines, regulatory frameworks and other documents related to population genetic screening programmes in Europe. Then, the questions that need debate, in regard to different types of genetic screening before and after birth, were examined. Screening for conditions such as cystic fibrosis, Duchenne muscular dystrophy, familial hypercholesterolemia, fragile X syndrome, hemochromatosis, and cancer susceptibility was discussed. Special issues related to genetic screening were also examined, such as informed consent, family aspects, commercialization, the players on the scene and monitoring genetic screening programmes. Afterwards, these questions were debated by 51 experts from 15 European countries during an international workshop organized by the European Society of Human Genetics Public and Professional Policy Committee in Amsterdam, The Netherlands, 19-20, November, 1999. Arguments for and against starting screening programmes have been put forward. It has been questioned whether genetic screening differs from other types of screening and testing in terms of ethical issues. The general impression on the future of genetic screening is that one wants to 'proceed with caution', with more active impetus from the side of patients' organizations and more reluctance from the policy-makers. The latter try to obviate the potential problems about the abortion and eugenics issues that might be perceived as a greater problem than it is in reality. However, it seems important to maintain a balance between a 'professional duty of care' and 'personal autonomy'.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Year:  2003        PMID: 14718938     DOI: 10.1038/sj.ejhg.5201113

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  35 in total

1.  Carrier screening in preconception consultation in primary care.

Authors:  Sylvia A Metcalfe
Journal:  J Community Genet       Date:  2011-12-20

2.  Perceived relevance of genetic carrier screening: observations of the role of health-related life experiences and stage of life in decision making.

Authors:  Alison D Archibald; Belinda J McClaren
Journal:  J Community Genet       Date:  2011-11-17

3.  Assessing the risks and benefits of diagnosing genetic conditions with variable phenotypes through population screening: Klinefelter syndrome as an example.

Authors:  Amy Simone Herlihy; Jane Halliday; Rob I McLachlan; Megan Cock; Lynn Gillam
Journal:  J Community Genet       Date:  2010-03-29

Review 4.  Carrier screening for beta-thalassaemia: a review of international practice.

Authors:  Nicole E Cousens; Clara L Gaff; Sylvia A Metcalfe; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

5.  The importance of program evaluation: how can it be applied to diverse genetics education settings?

Authors:  Sylvia A Metcalfe; MaryAnne Aitken; Clara L Gaff
Journal:  J Genet Couns       Date:  2008-02-05       Impact factor: 2.537

6.  Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report.

Authors:  B K Potter; D Avard; V Entwistle; C Kennedy; P Chakraborty; M McGuire; B J Wilson
Journal:  Public Health Genomics       Date:  2008-09-03       Impact factor: 2.000

7.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

8.  Evaluation after five years of the cancer genetic counselling programme of Valencian Community (Eastern Spain).

Authors:  Dolores Cuevas-Cuerda; Dolores Salas-Trejo
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

9.  Foetal surgery and using in utero therapies to reduce the degree of disability after birth. Could it be morally defensible or even morally required?

Authors:  Constantinos Kanaris
Journal:  Med Health Care Philos       Date:  2017-03

10.  Development of a fragile X syndrome (FXS) knowledge scale: towards a modified multidimensional measure of informed choice for FXS population carrier screening.

Authors:  Alice G Ames; Alice Jaques; Obioha C Ukoumunne; Alison D Archibald; Rony E Duncan; Jon Emery; Sylvia A Metcalfe
Journal:  Health Expect       Date:  2012-10-15       Impact factor: 3.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.